Both the DC and the DE measure showed an overall tendency for all of the deregulated genes, thus suggesting that the administered immunomodulatory drug activates the transcription of genes and increases their gene functional connectivity in MS patients; in other words, they acquire new interacting partners to engage in IFN-β-specific responses. This evidence concerns the gene IFNB1 and myeloid sarcoma.